Projects per year
- 1 - 50 out of 1,247 results
Search results
-
Active
-
HM2024-11: A PHASE III, MULTICENTER, RANDOMIZED, OPEN;LABEL STUDY COMPARING THEEFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTINPLUS RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA-R-CHP) VERSUSPOLATU
HOFFMANN-LA ROCHE PHARMACEUTICALS
4/5/24 → 4/30/34
Project: Research project
-
-
Dissecting mechanisms of sensitivity to B7-H3 (CD276)-targeted therapeutics in prostate cancer (PC)
Hwang, J., Antonarakis, E. & Zorko, N. A.
NIH NATIONAL CANCER INSTITUTE (NCI)
4/1/24 → 3/31/29
Project: Research project
-
A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition toeltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response orrelapsed after first line steroid treatment (VAYHIT2
NOVARTIS PHARMACEUTICALS CORPORATION
3/27/24 → 3/31/34
Project: Research project
-
Efgartigimod Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
3/14/24 → 3/31/34
Project: Research project
-
-
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of OralTinengotinib versus Physician s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refracto
TRANSTHERA SCIENCES (NANJING), INC.
2/26/24 → 2/28/34
Project: Research project
-
First-in-human Phase I, non-randomized, open-label, multi-center dose escalation trial of BI 765049 and BI765049 + ezabenlimab administered by repeated intravenous infusions in patients with malignant solidtumors expressing B7-H6
BOEHRINGER-INGELHEIM PHARMACEUTICALS
2/21/24 → 2/28/34
Project: Research project
-
MT2024-02: A Long-term Follow-up Study of Subjects With Malignancies Treated With CRISPR CARCellular Therapies
2/5/24 → 2/28/34
Project: Research project
-
Improving safety and access to immune effector cell therapy with artificial intelligence technology???
NIH NATIONAL CANCER INSTITUTE (NCI)
2/1/24 → 1/31/26
Project: Research project
-
Cancer Center Support Grant
Yee, D., Antonarakis, E., Beckman, K. B., Betts, B., Blaes, A. H., Eaton, A., Ellis, K. M., Felices, M., Geller, M. A., Ghebre, R. G., Griffin, T. J., Hallstrom, T. C., Harki, D. A., Hatsukami, D. K., Hirsch, B. A., Huang, R. S. S., Johnson, S., Juckett, M. B., Lange, C. A., Le, C. T., Luo, X., McKenna, D. H., Miller, J. S., Moriarity, B. S., Muretta, J. M., Murray, T., Nelson, H. H., Ondrey, F. G., Patel, M. R., Pennell, C. A., Petersen, A. J., Peterson, L. A., Poynter, J., Pratt, R. J., Sarver, A. L., Schendzielos, D. L., Schilz, A., Schwertfeger, K., Seelig, D., Shimizu, Y., Stepanov, I., Temiz, N. A., Ventz, S., Villalta, P. W., Vogel, R., Wagner, J. E., Wang, J., Webber, B. R., Weigel, B. J., Yamamoto, M. & Zhang, L.
NIH NATIONAL CANCER INSTITUTE (NCI)
2/1/24 → 1/31/29
Project: Research project
-
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab VersusTreatment of Physician s Choice in Patients With Triple Negative Breast Cancer Who Have ResidualInvasive Disease After Surgery and Neoadjuvant Therapy (AS
ALLIANCE FOUNDATION TRIALS, LLC, GILEAD SCIENCES, INC.
2/1/24 → 2/28/34
Project: Research project
-
-
-
Characterizing Health Care Contact Days as a Measure of Time Toxicity in Cancer Care
LAURA AND JOHN ARNOLD FOUNDATION
1/1/24 → 10/31/25
Project: Research project
-
An open label, multicenter roll-over extension program (REP) to characterize the long- term safety andtolerability of iptacopan (LNP023) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who havecompleted PNH Phase II and Phase III studies wit
NOVARTIS PHARMACEUTICALS CORPORATION
12/6/23 → 12/31/33
Project: Research project
-
Liver Tissue Distribution System (LTDS)
NATIONAL INSTITUTES OF HEALTH (NIH)
11/29/23 → 11/28/24
Project: Research project
-
A Phase 1, Open-label Study of Oral BDTX-4933 in Patients with KRAS, BRAF and Other Select RAS/MAPK Mutation Positive Neoplasms
BLACK DIAMOND THERAPEUTICS, INC
11/28/23 → 11/30/33
Project: Research project
-
A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination with Other Anticancer Therapies in Solid Tumors
10/6/23 → 10/31/33
Project: Research project
-
Firearm storage maps as a clinical tool to prevent suicide
Jewett, P. I. & Borowsky, I. W.
PROTECT MINNESOTA, THE DOCTORS COMPANY FOUNDATION
10/1/23 → 9/30/25
Project: Research project
-
USTMA Registry (P200)
US THROMBOTIC MICROANGIOPATHY ALLIANCE
10/1/23 → 9/30/26
Project: Research project
-
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), AnEGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with UnresectableLocally Advanced or Metastatic Cancer
TAKEDA DEVELOPMENT CENTER AMERICAS, INC.
9/28/23 → 5/31/33
Project: Research project
-
Cancer Center Survivorship Research Forum
NIH NATIONAL CANCER INSTITUTE (NCI)
9/18/23 → 8/31/24
Project: Research project
-
Increasing access to cancer trials in Minnesota (InACT-MN)
Erickson, B. K., Geller, M. A., Greeno, E. W., Kratzke, R. A., Ondrey, F. G., Teoh, D. G. & Yee, D.
NIH NATIONAL CANCER INSTITUTE (NCI)
9/18/23 → 8/31/28
Project: Research project